Carlos Graux

Onco-hematology

Pr Carlos GrauxProf. Carlos Graux MD, PhD

CHU UCL Namur, Site Godinne, Department of Hematology

Member of the Institute of Experimental and Clinical Research (IREC), UCLouvain

Manager of the Biobank of the CHU UCL Namur

Member of the Namur Thrombosis & Hemostasis Center (NTHC)

ORCID

Expertise and research interests

Bone marrow transplantation

Leukemia

Biobanking

Research projects

  • ONGOING A study of immune reconstitution in 52 patients treated with azacytidine and donor's lymphocytes for relapse of acute myeloid leukemia or myelodysplastic syndrome after allo stem cell transplantation. Ongoing PhD thesis by Dr. Charles Cassius. Joint PhD programme at Paris Diderot and UCLouvain (Prof. Carlos Graux).
  • Analysis of lymphocytes subpopulations in relapsed AML or MDS after allogeneic stem cell transplantation. Master thesis in medicine by Pierre-Yves Sansen. Under the supervision of Prof. Carlos Graux, CHU UCL Namur (2019).

  • L’utilisation des cellules CAR-T anti-CD19 dans le traitement des leucémies aiguës lymphoblastiques B. Master thesis in pharmaceutical sciences by Chiara Longo Sanchez Colero. Under the supervision of Porf. Carlos Graux, CHU UCL Namur (2019).

   In collaboration with UNamur

  • Study of the Role of TMEM45A in cancer resistance to chemotherapy. Collaborative research between Prof. Carine Michiels, UNamur; Prof. Carlos Graux, CHU UCL Namur, Prof. Lionel D'Hondt, CHU UCL Namur and Dr. Fabienne George, CHU UCL Namur.
  • Study of miR-126 involved in oncogenesis. Collaborative research between Prof. Benoît Muylkens, UNamur; Prof. Carlos Graux, CHU UCL Namur and Dr. Fabienne George, CHU UCL Namur.

Selected publications

De Wilde S, Graux C. Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T-cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report. Clin Case Rep. 2024 Jul 7;12(7):e9159.

Haguet H, Graux C, Mullier F, Dogné JM, Douxfils J. Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers (Basel). 2020 May 15;12(5):E1242.

Schmit K, Chen JW, Ayama-Canden S, Fransolet M, Finet L, Demazy C, D'Hondt L, Graux C, Michiels C. Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin. Cell Death Dis. 2019 Dec 4;10(12):919.

Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné JM. Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. Biomark Cancer. 2018 Jun 18;10:1179299X18781095.

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis. Expert Opin Drug Saf. 2017 Jan;16(1):5-12.

Contact

carlos.graux@chuuclnamur.uclouvain.be